MicroRNAs in Body Fluids: A More Promising Biomarker for Clear Cell Renal Cell Carcinoma

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2021 Oct 22

PMID 34675663

Citations 12

Authors

Lei Shi

Mengheng Wang

Haiping Li

Pengtao You

Affiliations

Soon will be listed here.

Abstract

Renal cell carcinoma (RCC) is the second most common cancer of the urinary system, accounting for approximately 10-15% of kidney cancers in the world. Clear cell renal cell carcinoma (ccRCC) is the most common RCC subtype with the highest mortality. Surgical resection or puncture of tumor tissue is still an important clinical treatment and diagnosis of ccRCC, but its high recurrence rate and poor prognosis often lead to the short survival period of patients. Hence, the development of novel molecular biomarkers is of great clinical importance. miRNAs are endogenous non-coding small RNAs with a length of 19-24 nt. A growing number of studies have reported that miRNAs, as proto-oncogenes or tumor suppressor genes, play a key role in the development of ccRCC and might be effective diagnostic and prognostic biomarkers. In addition, miRNAs can also predict the efficacy of treatment drug, thus improving the accuracy of clinical medication. Furthermore, non-invasive detection of miRNAs or extracellular vesicles (EV) in body fluids has better convenience and repeatability, which shows remarkable advantages compared with tissue detection. In this review, we summarized the typical miRNAs reported in recent years and place emphasis on evaluating miRNAs in different body fluids to provide reference for the clinical diagnosis and prognosis of ccRCC in the future.

Citing Articles

Diagnostic value of 5 miRNAs combined detection for breast cancer.

Jing Y, Huang X, Wang Y, Wang J, Li Y, Yelihamu D Front Genet. 2024; 15:1482927.

PMID: 39655225 PMC: 11625769. DOI: 10.3389/fgene.2024.1482927.

Chasing the Role of miRNAs in RCC: From Free-Circulating to Extracellular-Vesicle-Derived Biomarkers.

Mastrolia I, Catani V, Oltrecolli M, Pipitone S, Vitale M, Masciale V Biology (Basel). 2023; 12(6).

PMID: 37372161 PMC: 10295314. DOI: 10.3390/biology12060877.

Deregulated expression of the 14q32 miRNA cluster in clear cell renal cancer cells.

Chhabra R, Guergues J, Wohlfahrt J, Rockfield S, Espinoza Gonzalez P, Rego S Front Oncol. 2023; 13:1048419.

PMID: 37139155 PMC: 10150008. DOI: 10.3389/fonc.2023.1048419.

A review on the role of long non-coding RNA and microRNA network in clear cell renal cell carcinoma and its tumor microenvironment.

Zhang Q, Ren H, Ge L, Zhang W, Song F, Huang P Cancer Cell Int. 2023; 23(1):16.

PMID: 36732762 PMC: 9893571. DOI: 10.1186/s12935-023-02861-6.

A four-microRNA panel in serum may serve as potential biomarker for renal cell carcinoma diagnosis.

Li R, Chen W, Lu C, Li X, Chen X, Huang G Front Oncol. 2023; 12:1076303.

PMID: 36727070 PMC: 9885090. DOI: 10.3389/fonc.2022.1076303.

References

Keller S, Sanderson M, Stoeck A, Altevogt P . Exosomes: from biogenesis and secretion to biological function. Immunol Lett. 2006; 107(2):102-8. DOI: 10.1016/j.imlet.2006.09.005. View

Wang L, Yang G, Zhao D, Wang J, Bai Y, Peng Q . CD103-positive CSC exosome promotes EMT of clear cell renal cell carcinoma: role of remote MiR-19b-3p. Mol Cancer. 2019; 18(1):86. PMC: 6458839. DOI: 10.1186/s12943-019-0997-z. View

Rini B, Atkins M . Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009; 10(10):992-1000. DOI: 10.1016/S1470-2045(09)70240-2. View

Shi Y, Liu Z . Serum miR-92a-1 is a novel diagnostic biomarker for colorectal cancer. J Cell Mol Med. 2020; 24(15):8363-8367. PMC: 7412696. DOI: 10.1111/jcmm.15282. View

Lou N, Ruan A, Qiu B, Bao L, Xu Y, Zhao Y . miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma. Urol Oncol. 2016; 35(1):36.e7-36.e14. DOI: 10.1016/j.urolonc.2016.07.012. View

Huang G, Li H, Wang J, Peng X, Liu K, Zhao L . Combination of tumor suppressor miR-20b-5p, miR-30a-5p, and miR-196a-5p as a serum diagnostic panel for renal cell carcinoma. Pathol Res Pract. 2020; 216(11):153152. DOI: 10.1016/j.prp.2020.153152. View

Kosaka N, Iguchi H, Ochiya T . Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010; 101(10):2087-92. PMC: 11159200. DOI: 10.1111/j.1349-7006.2010.01650.x. View

Li G, Zhao A, Peoch M, Cottier M, Mottet N . Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma. Urol Oncol. 2017; 35(5):294-299. DOI: 10.1016/j.urolonc.2016.12.007. View

Qi Y, Wang L, Wang K, Peng Z, Ma Y, Zheng Z . New mechanistic insights of clear cell renal cell carcinoma from integrated miRNA and mRNA expression profiling studies. Biomed Pharmacother. 2019; 111:821-834. DOI: 10.1016/j.biopha.2018.12.099. View

10.

Koren E, Fuchs Y . The bad seed: Cancer stem cells in tumor development and resistance. Drug Resist Updat. 2016; 28:1-12. DOI: 10.1016/j.drup.2016.06.006. View

11.

Petrozza V, Costantini M, Tito C, Giammusso L, Sorrentino V, Cacciotti J . Emerging role of secreted miR-210-3p as potential biomarker for clear cell Renal Cell Carcinoma metastasis. Cancer Biomark. 2019; 27(2):181-188. DOI: 10.3233/CBM-190242. View

12.

Xiao W, Wang C, Chen K, Wang T, Xing J, Zhang X . MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2. EBioMedicine. 2020; 51:102622. PMC: 6948168. DOI: 10.1016/j.ebiom.2019.102622. View

13.

Bedke J, Albiges L, Capitanio U, Giles R, Hora M, Lam T . The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. Eur Urol. 2021; 80(4):393-397. DOI: 10.1016/j.eururo.2021.04.042. View

14.

Sun B, Zhang J, Liu M, Guan L . RETRACTED: Alkannin inhibits proliferation, migration and invasion of hepatocellular carcinoma cells via regulation of miR-92a. Biomed Pharmacother. 2019; 114:108782. DOI: 10.1016/j.biopha.2019.108782. View

15.

Zhang L, Zhang S, Yao J, Lowery F, Zhang Q, Huang W . Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 2015; 527(7576):100-104. PMC: 4819404. DOI: 10.1038/nature15376. View

16.

Guo P, Sheng M, Liu H, Ju L, Yang N, Sun Y . Effects of miR-218-1-3p and miR-149 on proliferation and apoptosis of non-small cell lung cancer cells. Oncol Lett. 2020; 20(4):96. PMC: 7439122. DOI: 10.3892/ol.2020.11957. View

17.

Outeiro-Pinho G, Barros-Silva D, Aznar E, Sousa A, Vieira-Coimbra M, Oliveira J . MicroRNA-30a-5p: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples. J Exp Clin Cancer Res. 2020; 39(1):98. PMC: 7323611. DOI: 10.1186/s13046-020-01600-3. View

18.

Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J . Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015; 25(8):981-4. PMC: 4528056. DOI: 10.1038/cr.2015.82. View

19.

Gattolliat C, Couve S, Meurice G, Orear C, Droin N, Chiquet M . Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease. Int J Oncol. 2018; 53(4):1455-1468. PMC: 6086628. DOI: 10.3892/ijo.2018.4490. View

20.

Labriola M, Batich K, Zhu J, McNamara M, Harrison M, Armstrong A . Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. Clin Genitourin Cancer. 2019; 17(3):e513-e521. PMC: 7004481. DOI: 10.1016/j.clgc.2019.01.017. View